

Understanding and Engaging Stakeholders

Understanding the Importance of stakeholder Engagement in Successful Commencement and Completion of Project

Lecturer Name: Kazeem Oseni

Module Name: Understanding and Engaging Stakeholders

Module Code: LCLM5001

Student Name: Moyez Uddin

Student ID: 2410661

Assignment Title: Understanding the importance of stakeholder Engagement in successful commencement and completion of project

1. Introduction: Medtronic UK and the New Project

a) About the Company: Medtronic UK

Medtronic is an imposing global giant in the medical technology, services, and solutions industry. Although it physically and officially sits in Dublin, Ireland, it still boasts an impressive and vital presence all over the world, including an integral hub within the United Kingdom itself. As a large business organisation, Medtronic's massive scale and scope have been sequentially broken down into its major operational business streams, coined as Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. The United Kingdom operations can be considered an integral and vital part of Medtronic as a whole, primarily operating with an overriding focus on excellent sales and distribution networks, vital and elementary clinical support, and an integral research focus

b) Project Outline: "VitalLink" Wearable Device

The present critical activity is associated with the project named "VitalLink." The VitalLink project requires and mandates the fast-track development and launch of a wearable health device within a period of six months. The device would be capable of continuously and non-invasively monitoring three vital physiological functions: heart rate (HR), blood oxygen saturation levels SpO2, and sleep patterns. VitalLink would go perfectly with the brand and goal of Medtronic which is to provide information to the public about their own health and how to take care of themselves. This will allow people to make and healthy choices for themselves.

2. Strategic Appraisal and Situational Analysis

A complete situational analysis is absolutely necessary as it will enable the VitalLink project at Medtronic to be anchored within a larger corporation strategy and will help identify factors that will make it successful or unsuccessful within a very tight six months' timeline.

a) Strategic Fit and Project Objectives (SMART)

The VitalLink product launch marks a clear transition strategy adopted by Medtronic as it focuses on exploiting its core competencies in medical-grade monitoring and expanding vigorously into the rapidly growing market for health and preventative medicine. Diversification represents an imperative principle toward remaining relevant. The project, therefore, needs to be evaluated against specific and measurable SMART goals:

- **Specific:** The main objective aims at successful fulfillment of necessary regulatory approval procedures (such as UKCA approval) and successful launch activity for the VitalLink device among the general UK market.
- **Measurable:** The criteria for success are measured as selling at least 10,000 units within the first fiscal quarter after launch. At the same time, it should attain a high Customer Satisfaction Score with a rate of 85%.

- **Achievable:** It is an attainable goal because it will be able to make immediate use of existing and excellent R&D facilities as well as expertise in supply chain. Moreover, it would be aided by a large and committed £1M marketing budget.
- **Relevant:** It relates very well to Medtronic's overall strategy plan as it will enable it not only to diversify its sales but also to emerge as a very strong player within the emerging market for wearable health devices.
- **Time-bound:** The whole product life cycle will be timeboxed with strict deadlines to achieve product launch on or before [Date - May 2026] and then fulfillment of 10,000-unit Q1 sales by [3 Months Post Launch].

b) SWOT Analysis of Medtronic UK for VitalLink Launch

The SWOT analysis provides a vital internal and external assessment:

b) SWOT Analysis of Medtronic UK for VitalLink Launch

This detailed SWOT analysis reveals both Medtronic's powerful competitive foundation and key areas of vulnerability. Its primary Strengths include global brand reputation for clinical reliability and strong existing R&D capabilities underpinned by extensive clinical data and expertise in monitoring critical metrics like SpO₂ and HR. These strengths provide a high level of consumer trust and enable faster, more reliable algorithm development, conferring immediate clinical credibility to the VitalLink device. Significant Weaknesses exist, though, such as a lack of inherent experience in agile D2C marketing and a potentially slow-moving bureaucratic culture typical of large, highly regulated medical device firms. The high internal cost structure also may dampen retail pricing, necessitating rapid internal reorganisation and potentially contributing to project delays if bureaucracy is not managed appropriately.

The external environment offers significant Opportunities, underpinned by a long-standing, post-pandemic tail of consumer health consciousness, the stratospheric growth of telemedicine, and the strong NHS driver for prevention care technologies. These factors confirm a large, growing target market prepared to pay a premium for health assurance and offer potential for future B2B integration with UK health systems.

c) PESTLE Analysis-sometimes also termed as contextual factors:

This is strongly reflected in the PESTLE analysis, confirming that the environment is complex. Political factors include mandatory requirements around UKCA marking and potential friction in trade supply chains post-Brexit, with significant regulatory risk. Economic factors are dominated by high inflation and a cost-of-living crisis, reducing discretionary spending by consumers on premium products and making the core marketing challenge one of justified premium price points. Sociological factors are highly favorable, including observable, increasing demand for personalized wellness, confirming high relevance and a large target audience for VitalLink. Technological factors are continuous developments in miniaturized sensors and AI-driven analytics, forcing strong competitive pressure, with continuous R&D required to ensure the Vital Link's algorithms remain cutting-edge. Legal factors relate to adherence to GDPR and the Data Protection Act 2018, presenting a core challenge in terms of robust data governance and user consent frameworks from the Legal and QA teams.

3. The Challenges and The Roles of The Main Stakeholders

a) Who are the Stakeholders?

The following are the stakeholders in this project, critical for the six-month delivery. The VitalLink project involves a diverse set of stakeholders. The Key Internal Stakeholders: Product Development Team-which will be responsible for designing the device and providing features; Marketing & Branding-team, which plays an essential role in positioning the device among consumers and developing a campaign for launching the product; Sales & Distribution-as the UK market has been chosen as the launching point, Sales & Distribution needs to be impacted to ensure market access and logistics; Regulatory & Quality Assurance (QA)-as compliance with UKCA and ensuring security related to GDPR is required; and Executive Leadership/Sponsor-strategic leadership, budget provision, and the ultimate authority for the project. The Key External Stakeholders include: UK Regulatory Bodies (MHRA/UKCA)-market entry is legally dependent on their approval; Key Retail Partners (e.g., Boots, Amazon)-this is considered as the essential channel for consumer distribution; Clinical/Academic Consultants-they are required to get the required validation on the accuracy of the SpO2 and sleep algorithms; and the End Consumers-they are the final customers and source of revenue for the product.

b) Responsibilities, Roles, and Benefits

Successful role allocation ensures that maximal project benefit is derived. Product Development supply chain design, prototyping, and final specifications ensure the product is reliable and manufacturable, while Marketing & Branding supply the launch strategy and £1M campaign budget for Market Awareness, driving pre-launch demand. The Regulatory & QA team obtains UKCA marking, while also providing audit data protocols to ensure Compliance and Legality, thereby negating the principal risk of launch failure. The Executive Leadership provides project sponsorship and resource allocation to ensure Strategic Alignment, removing roadblocks within the organisation.¹ Externally, UK Regulatory Bodies legitimise the product through the provision of market authorisation, and Key Retail Partners provide essential Market Access/Distribution via credible, immediate routes to the consumer.

c) Problems and Theoretical Application

The development team has a lot of expectation that they will have to try to meet especially from stakeholders. The time limit being 6 months with a limited but appropriate budget might be tight but the top priority will be to create the required product in a manageable timeline.

For the Regulatory & QA team, their slow bureaucratic processes conflict directly with the commercial launch date, which reflects their high Power and Legitimacy (according to the Saliency Model by Mitchell, 1997) and thus requires careful, proactive management. At the same time, Executive Leadership may insist on unrealistic ROI or Q1 sales targets, which would again reflect a potential principal-agent gap between their objectives (shareholder value) and those of the project team (successfully bringing the product into the market), a dynamic studied under Agency Theory.

We need to be able to control our resources such as storage and advertising budget by working in tandem with our key retail partners. The dynamics of resource dependency theory (Pfeffer & Salancik), dictates that we cannot use these resources with the proper permissions and care put into it.

4. The Models and Frameworks Used for The Stakeholders:

a) Systematic application of the Power/Interest Matrix

allowed for appropriate management strategies. Key Players: those characterized by High Power/High Interest, which in this case included Executive Leadership and Regulatory/QA, required the "Manage Closely" approach of proactively keeping them involved in significant decisions and maintaining the support of, and agreement on, their positions. Stakeholders within the "Keep Satisfied" quadrant, comprising Sales & Distribution and IT/Security, who have High Power/Low Interest, received high-level summaries with essential needs satisfied but without overly weighted details that may distract or put them to sleep.² Whereas the "Keep Informed" group was mostly the Marketing/Branding Team and the Clinical Consultants with low power and high interest, presented with regular, very detailed information so that their interest level could be utilized properly to glean constructive suggestions without having to give up decision-making responsibility.

b) RACI Matrix

The RACI Matrix was used to clarify executive roles and remove ambiguity, a common cause of conflict. For example, Regulatory/QA was placed Accountable (A) for the final device specs sign-off and attainment of UKCA approval, whereas the technical work was with Product Development, Responsible (R). On the other hand, the Executive Sponsor was uniquely Accountable (A) for final approval of the launch date, considering the input of all relevant stakeholders. With this matrix, clarity was defined as to ownership, consultation, and implementation concerning key activities and, therefore, acceleration in the process of making decisions.

c) Stakeholder Engagement and Communication Plan (Outline)

A formalised Engagement and Communication Plan ensured consistency and targeting of engagement. The consistent contact with Executive Leadership was through Formal Steering Committee Meetings on a bi-weekly basis to lock in final approvals, as befits their High-Power, High-Interest status. The Product Development team, given the very tight schedule, needed near-constant engagement via Daily Stand-ups and Technical Workshops. Regulatory & QA, given the critical risk around compliance, were put onto a regime of mandatory Weekly Dedicated Compliance Review Sessions. Lastly, Key Retail Partners, important for placing stock and ensuring reliable distribution, were managed on a "Keep Satisfied" basis via Monthly Contract Negotiation Meetings and weekly logistics updates.

5. Process of Stakeholder Involvement and Conflict Management

Accordingly, as a Project Manager, it is important to approach the engagement process in a systematic way, which calls for proactive conflict management using established models.

a) The Stakeholder Engagement Process: The 5-Step Cycle

The engagement process is a continuous process. It happens in the form of a cycle: Identify → Analyse → Plan → Engage → Monitor.

1. Identify: Initial mapping of all parties using brainstorming and historical data. Example: The identification of the need for an IT Security team due to GDPR.
2. Analyze: Use the Power/Interest Matrix and Salience Model to determine level of stake, influence, and legitimacy. This defines their priority level. Example: Regulatory/QA = High Power/High Interest
3. Plan: Develop the Engagement Plan and RACI Matrix to identify what needs to be done and who should perform these activities. Example: Weekly Planning for Regular Compliance Check-in with Regulatory
4. Engage: Putting the Communications Plan into practice; formal meeting, reports, and informal relationships-building - soft skills. Trust is built here more than anywhere else.
5. Monitor/Review: Ongoing effectiveness of the engagement. Are stakeholders satisfied? Do they raise new issues? This again feeds back into the Analyse stage through which the strategy can be dynamically adjusted. Example: Employ a simple stakeholder satisfaction survey-score 1-5 after major milestones.

b) Project Manager's Role - Responsibilities

The PM is the communication nexus, a translator of technical, commercial, and regulatory language, and finally the Conflict Mediator.

- Translator: Translate technical risks from R&D into business, simple, impactful decisions to be taken by the Executive team.
- Negotiator: Facilitate the trade-off among the marketing team's required date of launch versus that of the regulatory team for compliance.
- Scope Custodian: Protect the project against uncontrolled changes by internal stakeholders better known as scope creep.
- Communicator-in-Chief: Ensuring that information is consistent, customized, and timely to flow as defined by the Communication Plan.

c) Conflict Management: 4 C's Model-the Conflict Resolution Strategy

1. Communication: It is important to maintain clear communication among the required parties to make sure any environment thrives. This can be affected through: placing a 'No Surprises' rule whereby bad news is told immediately and straight; using one risk register so conflicts are out in the open and not hidden.

2. Coordination: Activities are aligned, and interdependencies are known. The conflict arises when one team executes work that it is unaware the other is blocking. Action: RACI Matrix enforcement and application of common project management software, such as Jira/MS Project, to identify dependencies.

3. Collaboration: Fostering a team spirit where partners would readily avail their services towards the accomplishment of the shared goal, which is the successful launch, even if it has to be at some cost to their departmental short-term needs or advantage.

4. Cooperation: A high-level conflict resolution where the different stakeholders together explore solutions that satisfy the parties' needs.

6. Impact Analysis, Recommendations and Conclusion

a) Business Performance Impact Assessment

Effective and systematic stakeholder engagement is not some peripheral administrative task; it's a strategic function that transforms the project environment from one of disparate departmental tasks to a coherently integrated high-performance system, which has a direct and demonstrable impact on business performance and financial outcomes at Medtronic.

1. Risk Mitigation, Compliance, and Legality

The application of the strategy Manage Closely to the High Power/High Interest stakeholder, the Regulatory & Quality Assurance QA team, proved particularly effective in navigating the project through the complex transition to UKCA marking and adherence to strict GDPR protocols. Proactive engagement through dedicated, regular compliance reviews was performed according to the Communication Plan, which made sure that the technical specification was compliant prior to major manufacturing investment. That will prevent a catastrophic business failure-selling a non-compliant medical device-before it happened. The devastating consequences would have included:

Huge fines and attendant legal penalties.

- Mandatory product recalls-the direct effect on revenue.
- Permanent, severe damage to Medtronic's reputation for clinical reliability

Ultimately, effective engagement with the QA team served as an important insurance policy that protected brand value and preserved projected streams of revenues. The cost of the engagement in terms of time and meetings was many orders of magnitude less than the potential cost of non-compliance.

2. Increased Speed to Market & Revenue

The high level of pressure caused by the six-month deadline was managed by close collaboration and coordination-two of the 4C's-with the Product Development and Manufacturing teams. Well-defined decision-making authority through the RACI Matrix prevented delays caused by 'decision paralysis.' Daily stand-ups and technical workshops optimized technical sign-offs and production ramp-up, thereby reducing lead times. Meeting the launch deadline of 6 months has a direct financial benefit in that every week of delay is a week of lost revenue generation to competitors.

The seasonal market is very important for any company so fishing everything and launching during that time is essential to make sure we can reach the Q1 target sales which is 10,000-units.

3. Making Sure the Product Fits Our Market and Increases Profit Margins

Early and continuous involvement with Key Retail Partners and Clinical Consultants furnished valuable, actionable market intelligence. The Retail Partners-years managed to Keep Satisfied-confirmed the premium market position was indeed viable, as there would be sufficient demand for the clinically backed device over mass-market competitors. The Clinical Consultants confirmed the requirement of

the SpO₂ feature. This was a good enough reason to include it. However, intelligence that was gleaned helped the Marketing team-managed to Keep Informed-to confidently target a higher-than-average consumer price point, positioning VitalLink as the "clinical-grade choice."

- Result: This strategic engagement had an immediate effect on the profit margin per unit, trickled into a positive Medtronic revenue, and ultimately into shareholder value. In this way, it helped them avoid one of the most common failures: "To launch a product with features the market doesn't value, or at a non-competitive price."

4. Building Reputation, Trust, and Intangible Assets

In a healthcare organisation, trust is the core intangible asset. Proactive communications and conflict management were affected with Executive Leadership to instill confidence in project execution. By allowing Low Power/High Interest to participate in limited early access programs and focus groups, Medtronic opens transparency to user needs. A successful, transparently managed launch reinforces the Medtronic brand, synonymous with reliable consumer wellness. This will be an asset critical to building a pipeline of future consumer products and invaluable to future B2B opportunities, such as partnerships with the NHS for remote patient monitoring.

5. Efficiency Gains and Cost Control

Formal project management frameworks, particularly the RACI Matrix, ensured that there would be no disturbance in operational efficiency. In clarification, the said matrix indeed dispelled confusion as to who is responsible versus who is singularly accountable for each deliverable. It thus avoided duplicated effort, which always resulted in costly rework and scope creep. For example, knowing the regulatory team was accountable for final specs stopped R&D from making costly last-minute, non-compliant changes. This adherence to defined roles meant the project remained strictly within its allocated \$£1M marketing and development budget, supporting crucial financial performance metrics and demonstrating robust capital management.

7. Recommendations for Future Stakeholder Engagement

As such, the compliance and timeliness of launching VitalLink rendered Medtronic with a strong template to replicate future consumer-facing health technology initiatives. Based on the SWOT analysis, key strategic suggestions to keep momentum going and best practices institutionalized include the following:

1. Institutionalisation of Standard Operating Procedure

- **Training & Integration:** Provide cross-functional training for Project Managers and functional leads. The approach is vital in managing the inherent difficulties of a large medical device firm's culture.
- **Cultural Shift:** This is where the Executive Sponsor as a core organisational value should reward teams through publicity that have successfully and collaboratively resolved their conflict, hence reinforcing the required shift in cultural behavior.

2. Design a Stakeholder Engagement Performance Indicator (SPI)

When it gets completed on schedule and within its budget, that says nothing about the quality of the engagement. There's a need to have some sort of metric that can measure relational health.

- **Implementation:** Implement the mandatory project KPI that actually reflects Stakeholder Satisfaction. It shall be formalised by a lightweight Net Promoter Score for key stakeholders via a short survey after major milestones.
- **Accountability:** The SPI should be formally tied to the Project Manager's and key Functional Lead performance reviews, so that the quality of engagement is not an optional activity but a critical success factor.

3. Invest in Digital Tools of Engagement and Transparency

Finally, to counterbalance the teams spread across the globe and reduce bureaucratic latency, digital platforms require transparency and should simplify information flow-in other words, reduce the latency introduced by the 'slow-moving culture' weakness.

- **Centralised Platform:** Implement an organisational-wide, cloud-based Project Management Information System in (PMIS). Store all crucial project documents on the said platform. These shall comprise but not be confined to: the signed-off RACI matrix, live risk register, key communication logs, and formal change requests.
- **Improved Coordination:** It will raise transparency among High-Interest stakeholders through one version of the truth. It enhances coordination and reduces reliance on long email chains and much manual status reporting by a great degree.
- **Efficiency Gains:** Automation of status reporting for the Low Power/ Low Interest stakeholders-examples include General Employees-will free the PM to concentrate their efforts with the High Power/High Interest 'Key Players'.

4. Establish a standing/future-oriented advisory committee on 'future-proofing'.

Consumer health technology is also subject to a high risk of rapid technological obsolescence and alters regulations concerning such issues as GDPR and ethics of AI. This calls for there being institutionalised consultations externally.

Panel Formation: There should be the formation of a standing Advisory Panel composed of external experts, which includes Clinical Consultants specialising in remote monitoring, IT Security / Data Privacy Experts, and Consumer Law Specialists.

Compulsory Consultation: We convene this panel for binding continuous consultation in the concept and feasibility phases of all new consumer devices projects.

- **Risk Mitigation:** This will institutionalize access to expert leading-edge knowledge and proactively mitigate the risk of rapid technological obsolescence and emerging regulatory threats well before they have any significant costs because of mid-project conflicts or extensive redesigns.

5. Formalise the mediation authority of the Project Manager

This requires empowering the mediator role of the PM to take up intrinsic 'slow-moving culture' and avoid the pitfalls of 'decision paralysis.'

- **Clearly State the Authority:** Provide the Project Manager with documented and formal authority, clearly endorsed through the Executive Sponsor, to call mandatory joint problem-solving-also known as Collaboration-when there are functional conflicts that cannot be resolved at the department level within a fixed 48-hour period.

- **Timely Decision Making:** Availing this authority will ensure that disputes are referred to and resolved without causing bureaucratic delays, which is the most critical component in timely decision-making. It ensures that bottlenecks should not have a negative impact on any part of the process, and the results would be to keep the integrity of the project schedule intact. This is an essential mechanism to ensure that the 'Time-bound' SMART objective can always be met in future projects.

6. Enhance Consumer Engagement Strategy beyond Launch

Current is extremely internal and commercially focused. This needs to be solidified into the currently running projects as to guarantee a continuing success through perpetual involvement with the end user: Low Power/High Interest.

Community building: This needs to focus on building an online community of users where customers can share experiences concerning usage and data. This will enable Medtronic to abstract organic market intelligence from that platform and, in the process, create a sense of loyalty, therefore diffusing the intense rivalry by established technology giants. These six strategic recommendations cooperate and intersect to help institutionalize the agility, rigor of compliance, and collaborative spirit that made the success of the VitalLink project possible. The ad-hoc experience could be transformed into a repeatable high-performing organisational capability.

8. Conclusion

On-time market release within the aggressive six-month timeline and compliantly-a successful 'go-live' experience of the VitalLink wearable health device-is a big strategic success for Medtronic UK. The success within this ambitious six-month timeline has been anything but an accident; it relates intrinsically to the presence of solid, systematic application of proactive mechanisms for the involvement of stakeholders.

The project was underpinning in the strategic context of Medtronic UK through the use of the SWOT/PESTLE analysis, which clearly defined market opportunities and regulatory threats. Subsequent realization of essential project management frameworks (Power/Interest Matrix/RACI Matrix) then gave form. These enabled effective stakeholder identification and grouping for high-priority stakeholders such as Regulatory/QA and Executive Leadership, to whom the Project Manager could then assign strategies for their engagement that would migrate from mere information sharing to intense management for ensuring collective alignment. Notably, the role of the Project Manager in conflict mediation was backed by the effective application of the 4C's Model: Communication, Coordination, Collaboration and Cooperation. This model proved to be the critical differentiator in conflict management, enabling the cross-functional team to transcend the inefficient compromise to achieve true Collaboration. This approach has produced constructive resolution of the inherent, high-stakes tension between market speed driven by Marketing and the non-negotiable clinical compliance driven by Regulatory. In all, this report shows that active stakeholder engagement is anything but a 'soft skill'; it is a measurable driver of business performance. This approach alleviated critical risk factors related to compliance immensely, brought down the time-to-market for the project, maintained profitable budgets through improved efficiency, and, more importantly, sustained the precious clinical reputation of Medtronic. This would ensure a profitable and strategically sound entry into the consumer health business.

References

1. Freeman, R.E., Harrison, J.S. and Zyglidopoulos, S. (2018) *Stakeholder Theory*, Cambridge University Press eBooks. <https://doi.org/10.1017/9781108539500>.
2. Joos, H.C., Knyphausen-Aufseß, D.Z. and Pidun, U. (2020) 'Project stakeholder management as the integration of stakeholder salience, public participation, and nonmarket strategies,' *Schmalenbach Business Review*, 72(3), pp. 447–477. <https://doi.org/10.1007/s41464-020-00092-0>.
3. Kerzner, H. (2022) *Project management: A Systems Approach to Planning, Scheduling, and Controlling*. Wiley.
4. Kibathi, R.G. and Nyang'au, S. (2023) *STAKEHOLDER ENGAGEMENT AND PERFORMANCE OF HEALTH PROJECTS IN PUBLIC HOSPITALS IN NYERI COUNTY, KENYA*. <https://www.sagepublishers.com/index.php/ijssme/article/view/260>.
5. Serna, L.R., Nakandala, D. and Bowyer, D. (2022) 'Stakeholder identification and prioritization: The attribute of dependency,' *Journal of Business Research*, 148, pp. 444–455. <https://doi.org/10.1016/j.jbusres.2022.04.062>.
6. Yao, R. *et al.* (2022) 'Inequities in health care services caused by the adoption of digital health Technologies: Scoping review,' *Journal of Medical Internet Research*, 24(3), p. e34144. <https://doi.org/10.2196/34144>.
7. Chen, Y. *et al.* (2020) 'Strain engineering and epitaxial stabilization of halide perovskites,' *Nature*, 577(7789), pp. 209–215. <https://doi.org/10.1038/s41586-019-1868-x>.
8. Petkovic, J. *et al.* (2023) 'Key issues for stakeholder engagement in the development of health and healthcare guidelines,' *Research Involvement and Engagement*, 9(1), p. 27. <https://doi.org/10.1186/s40900-023-00433-6>.
9. Pereno, A. and Eriksson, D. (2020) 'A multi-stakeholder perspective on sustainable healthcare: From 2030 onwards,' *Futures*, 122, p. 102605. <https://doi.org/10.1016/j.futures.2020.102605>.
10. Martin, E., Nolte, I. and Vitolo, E. (2016) 'The Four Cs of disaster partnering: communication, cooperation, coordination and collaboration,' *Disasters*, 40(4), pp. 621–643. <https://doi.org/10.1111/disa.12173>.